Table 3.

ICCs over 2 to 3 y for other cancer-related biomarkers among premenopausal and postmenopausal women in the NHS and NHSII

AnalyteNo. of participants/number of time pointsCV (%)Median (5th-95th percentile)Within-person CVBetween-person CVICC (95% CI)
Postmenopausal
 MMPs, plasma (ng/mL)
  MMP140/210.51.42 (0.28–5.24)26.485.50.91 (0.84–0.95)
  MMP240/217.8158 (119–204)9.815.00.69 (0.51–0.83)
  MMP340/210.48.67 (5.56–16.3)25.927.70.52 (0.31–0.73)
  MMP740/217.52.04 (1.28–4.33)17.333.00.78 (0.62–0.88)
  MMP940/213.872.3 (30.8–286)62.418.30.07 (0.00–0.91)
 BSL, plasma (ng/mL)68/324.98.30 (3.00–27.2)39.050.80.62 (0.50–0.73)
 Soluble leptin receptor, plasma (ng/mL)35/27.44.33 (3.74–4.69)12.026.00.82 (0.68–0.90)
 Resistin, plasma (ng/mL)35/212.02.34 (1.85–3.14)18.532.00.74 (0.57–0.86)
 Melatonin, plasma (pg/mL)40/211.54.46 (1.85–52.09)57.977.40.63 (0.44–0.79)
Premenopausal
 Melatonin, plasma (pg/mL)40/26.97.19 (0.17–85.3)88.280.00.44 (0.22–0.68)